Emzor Pharmaceutical Industries Ltd has successfully repaid its inaugural Series 1 Commercial Paper, a ₦5.13 billion note issued in November 2024 under its ₦10 billion Commercial Paper Issuance Programme. The maturity on August 18, 2025, marks a milestone in the company’s capital market engagement and reinforces its financial credibility in Nigeria.
“This repayment demonstrates our commitment to financial discipline and investor confidence. Emzor remains steadfast in promoting innovation, quality, and self-reliance in pharmaceutical manufacturing,” the company stated.
The company is simultaneously advancing local production of Active Pharmaceutical Ingredients (APIs) through a $23 million investment in a state-of-the-art facility in Sagamu, Ogun State—the first of its kind in Sub-Saharan Africa.
The facility, nearing completion with over 90% of civil works done, is expected to open in early 2026. It is designed to produce key medicines, including antimalarials and HIV/AIDS antiretrovirals, reducing Nigeria’s reliance on imports and lowering production costs.
“The API plant is central to Nigeria’s drive for drug self-sufficiency. Our R&D lab has already developed five antimalarial APIs in preparation for full-scale production,” Emzor added.
Emzor has also invested in digital solutions for drug safety, deploying Oracle ERP and track-and-trace technology across its supply chain to enhance inventory management, monitor medicine quality, and combat counterfeit drugs.
The company’s regional reach continues to expand, with over 200 registered products manufactured across multiple sites and distributed to all Nigerian states, as well as exports to Liberia and Sierra Leone. At the recent ECOWAS@50 summit in Lagos, Emzor reaffirmed its commitment to medicine security and healthcare accessibility across West Africa.
Government policies have further supported Emzor’s local production. The company benefits from a two-year exemption on import duties and VAT for pharmaceutical raw materials, alongside the “Nigeria-First Policy”, which prioritises procurement of locally manufactured goods for federal agencies.
“
These policies align with our backwards integration strategy, allowing us to expand local production and make essential medicines more affordable,” the company said.
Emzor’s simultaneous achievements—timely commercial paper repayment, infrastructure investment, digital innovation, and regulatory alignment—underscore its position as a leader in Nigeria’s pharmaceutical sector. As the API plant nears completion and distribution networks grow, Emzor is positioning itself at the forefront of resilient, locally driven healthcare solutions across Africa.
